NORTHLAND

NORTHLAND

Language

Holding subsidiary Huonland makes its debut at the 21st National Ophthalmology Annual Conference.

发布时间：2016-09-14

From September 8 to 11, 2016, the 21st National Ophthalmology Academic Conference of the Chinese Medical Association was held at the Suzhou International Expo Center. Professional ophthalmic pharmaceutical manufacturers and ophthalmic device companies from 17 countries around the world participated in the conference and engaged in academic exchanges. Huiren Landtech exhibited at the show, debuting its newly developed, independently researched products for the first time and receiving considerable attention. During the exhibition, more than 600 ophthalmologists and 400 distributors visited the booth to learn about the company and its products. Among the exhibitors were well-known domestic and international companies in the ophthalmology field, including Novartis, Abbott, Alcon, Bausch + Lomb, Santen, and Shenyang Xingqi.

17

2016-08

NORTHLAND Selected for Beijing's Biomedical Industry "G20 Project"

发布时间：2016-08-17

On August 16, 2016, the Beijing Municipal Science and Technology Commission released the first batch of G20 enterprise list for the 13th Five-Year Plan period, and NORTHLAND was successfully selected as an innovation-leading enterprise.

27

2016-06

The discussion meeting on the Phase I clinical trial protocol for Recombinant Human Thymosin β4 for Injection (NL005) was successfully held.

发布时间：2016-06-27

On June 23, 2016, the discussion meeting on the Phase I clinical trial protocol for Recombinant Human Thymosin β4 for Injection (NL005), hosted by Beijing Northland Biotechnology Co., Ltd., was successfully held at the Kyoto Xinyuan Hotel in Beijing.

08

2016-06

Huienland Company has been granted approval for the clinical trial of moxifloxacin hydrochloride eye drops.

发布时间：2016-06-08

11

2016-04

The mid-term seminar for the Phase III clinical trial of “△1-9, Alanine 10, Asparagine 134, Recombinant Human Interleukin-11” was successfully held.

发布时间：2016-04-11

To further strengthen the quality management of clinical trials, discuss issues arising during the trial process, and promote the exchange of experiences among research centers, the mid-term seminar for the Phase III clinical trial of “△1-9, Alanine 10, Asparagine 134, Recombinant Human Interleukin-11” was successfully held on April 9, 2016, at the Sheraton Yongtai Hotel in Beijing. Professor Hu Xichun, the principal investigator from the leading study institution—the Fudan University Affiliated Tumor Hospital—and representatives of investigators from more than ten participating research institutions attended the meeting.

01

2016-02

The 2016 NORTHLAND annual meeting was successfully held.

发布时间：2016-02-01

On January 29, 2016, the 2015 Work Summary and Awards Ceremony of NORTHLAND was successfully held at the Daoxiang Lake View Hotel. At the meeting, Executive Vice President Nie Liya summarized and reviewed the company's achievements and existing challenges in 2015, and outlined the key priorities for 2016. Following that, employees who had excelled in this year's performance evaluations were honored with certificates and prizes; employees who had joined the stock ownership plan received honorary certificates; and employees who had been with the company for more than ten years were presented with commemorative gold coins. Chairman and President Xu Songshan announced the restructuring of the company’s organizational structure, introduced the two newly appointed senior executives, and delivered a concluding speech. On behalf of the company’s board of directors, he thanked all employees for their hard work throughout the past year and set forth specific requirements for 2016. He urged all employees to focus on the overarching goal of “the Year of Market Development,” actively cultivate market development capabilities, standardize research, management, and operational practices, work together in unity, embrace change, strengthen corporate culture building, and improve work quality and efficiency. He encouraged everyone to keep pace with the company’s development, go all out to fulfill the annual work plan, and promptly revise the company’s medium- and long-term development plans as needed.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

Follow Us

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

WeChat Mini Program

Web site

WeChat Official Account

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license

Powered by 300.cn  Privacy Policy